PURPOSE: Pathfinders is a multi-faceted psychosocial care program for cancer patients; it was developed in community oncology and adapted to the academic oncology setting. This prospective, single-arm, phase 2 pilot study examined the acceptability and feasibility of Pathfinders for women with metastatic breast cancer. METHODS: Over 3 months, participants completed patient-reported surveys including the Patient Care Monitor (PCM, review of systems), Functional Assessment of Chronic Illness Therapy-Breast Cancer (FACT-B), Self Efficacy, and a single-item survey asking patients whether the program was helpful to them. A technology-based data collection system was used to capture electronic patient-reported outcomes at point of care, report symptoms in real time to clinicians, and collect warehouse data to provide a detailed longitudinal picture of the patient experience when receiving Pathfinders. RESULTS: Participants (n = 50) were: mean age 51 (SD 11); 76% white, 20% black; 74% married; 50% college degree. Forty-two (n = 42) patients completed baseline and 3-month assessments. Statistically significant improvements (all P < 0.05) occurred in PCM subscales for Distress (mean [SE] = -3.42 [1.21]), Despair (-4.53 [1.56]), and Quality of Life (2.88 [0.97]), and the FACT-B Emotional Wellbeing subscale (2.07 [0.46]). Of the 29 participants asked if Pathfinders was helpful, 27 (93%) responded positively and two did not respond. Other instruments measuring symptoms, quality of life, and self-efficacy showed improvement. CONCLUSIONS: In a phase 2 pilot study, Pathfinders was helpful to patients and is feasible in an academic medical center. Follow-up data collected at the 3-month assessment suggest that the program impacts various psychological outcomes, notably distress and despair.
PURPOSE: Pathfinders is a multi-faceted psychosocial care program for cancerpatients; it was developed in community oncology and adapted to the academic oncology setting. This prospective, single-arm, phase 2 pilot study examined the acceptability and feasibility of Pathfinders for women with metastatic breast cancer. METHODS: Over 3 months, participants completed patient-reported surveys including the Patient Care Monitor (PCM, review of systems), Functional Assessment of Chronic Illness Therapy-Breast Cancer (FACT-B), Self Efficacy, and a single-item survey asking patients whether the program was helpful to them. A technology-based data collection system was used to capture electronic patient-reported outcomes at point of care, report symptoms in real time to clinicians, and collect warehouse data to provide a detailed longitudinal picture of the patient experience when receiving Pathfinders. RESULTS:Participants (n = 50) were: mean age 51 (SD 11); 76% white, 20% black; 74% married; 50% college degree. Forty-two (n = 42) patients completed baseline and 3-month assessments. Statistically significant improvements (all P < 0.05) occurred in PCM subscales for Distress (mean [SE] = -3.42 [1.21]), Despair (-4.53 [1.56]), and Quality of Life (2.88 [0.97]), and the FACT-B Emotional Wellbeing subscale (2.07 [0.46]). Of the 29 participants asked if Pathfinders was helpful, 27 (93%) responded positively and two did not respond. Other instruments measuring symptoms, quality of life, and self-efficacy showed improvement. CONCLUSIONS: In a phase 2 pilot study, Pathfinders was helpful to patients and is feasible in an academic medical center. Follow-up data collected at the 3-month assessment suggest that the program impacts various psychological outcomes, notably distress and despair.
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Amy P Abernethy; James E Herndon; Jane L Wheeler; Meenal Patwardhan; Heather Shaw; H Kim Lyerly; Kevin Weinfurt Journal: Health Serv Res Date: 2008-08-28 Impact factor: 3.402
Authors: Sophia K Smith; James E Herndon; H Kim Lyerly; April Coan; Jane L Wheeler; Tina Staley; Amy P Abernethy Journal: Psychooncology Date: 2011-05 Impact factor: 3.894
Authors: Sophia K Smith; Jonathan D O'Donnell; Amy P Abernethy; Kristin MacDermott; Tina Staley; Gregory P Samsa Journal: Psychooncology Date: 2015-01-28 Impact factor: 3.894
Authors: Z Li; W L Leite; L A Thompson; H E Gross; E A Shenkman; B B Reeve; D A DeWalt; I-C Huang Journal: Clin Exp Allergy Date: 2016-10-21 Impact factor: 5.018
Authors: Erin L O'Hea; Alexandra Cutillo; Laura Dietzen; Tina Harralson; Grant Grissom; Sharina Person; Edwin D Boudreaux Journal: Contemp Clin Trials Date: 2013-02-07 Impact factor: 2.226
Authors: Erin O'Hea; Aimee Kroll-Desrosiers; Alexandra S Cutillo; Hannah R Michalak; Bruce A Barton; Tina Harralson; Cindy Carmack; Cori McMahon; Edwin D Boudreaux Journal: Patient Educ Couns Date: 2019-11-05